Unnamed: 0,title,date,stock,sentiment
425791.0,"Enanta Pharmaceuticals Q2 EPS $(0.300) May Not Compare To $(0.870) Estimate, Sales $27.600M Miss $27.640M Estimate",2020-05-06 16:31:00-04:00,ENTA,negative
425792.0,"Baird Upgrades Enanta Pharmaceuticals to Outperform, Announces $60 Price Target",2020-03-17 07:30:00-04:00,ENTA,neutral
425793.0,Enanta Pharma Reports Will 'Leverage Proven Antiviral and Respiratory Expertise to Evaluate Existing Compounds and New Approaches for Treating the Coronavirus',2020-03-13 07:07:00-04:00,ENTA,neutral
425794.0,"Enanta Pharmaceuticals Q1 EPS $0.65 Beats $0.58 Estimate, Sales $52.6M Miss $58.86M Estimate",2020-02-06 16:00:00-05:00,ENTA,negative
425795.0,JMP Securities Downgrades Enanta Pharmaceuticals to Market Perform,2019-11-22 07:17:00-05:00,ENTA,positive
425796.0,Enanta Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q4 EPS and sales results.,2019-11-21 16:05:00-05:00,ENTA,neutral
425797.0,"Enanta Pharmaceuticals Q4 EPS $0.44 Misses $0.53 Estimate, Sales $51.313M Miss $55.94M Estimate",2019-11-21 16:01:00-05:00,ENTA,negative
425798.0,Enanta Pharmaceuticals Announces 3 Poster Presentations at The Liver Meeting 2019,2019-11-11 07:37:00-05:00,ENTA,neutral
425799.0,"Enanta Pharma Highlights New Data From Co.'s Phase 2a Human Challenge Study Of EDP-938 For RSV Showed Highly Statistically Significant Reductions in Total Symptom Score, Mucus Weight and RSV Viral Load as Measured by RT-PCR Assay and by Plaque Assay",2019-10-03 07:38:00-04:00,ENTA,positive
425800.0,Enanta Pharmaceuticals shares are trading lower after JP Morgan downgraded the company from Neutral to Underweight and lowered the price target from $86 to $57.,2019-09-26 07:57:00-04:00,ENTA,positive
425801.0,"JP Morgan Downgrades Enanta Pharmaceuticals to Underweight, Lowers Price Target to $57",2019-09-26 06:48:00-04:00,ENTA,positive
425802.0,"Enanta Announces ARGON-1 Study Of FXR Agonist, EDP-305, For The Treatment Of NASH Met Primary And Key Secondary Endpoint",2019-09-25 16:01:00-04:00,ENTA,neutral
425803.0,"Enanta Pharmaceuticals Q3 EPS $0.33 Beats $0.16 Estimate, Sales $44.4M Miss $46.98M Estimate",2019-08-06 16:00:00-04:00,ENTA,negative
425804.0,Enanta's HCV Collaboration Partner AbbVie Receives Approval By European Commission For MAVIRET To Shorten Treatment Duration To Eight Weeks For Treatment-Na√Øve HCV Patients With Compensated Cirrhosis,2019-08-02 08:54:00-04:00,ENTA,positive
425805.0,"Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-514, its Lead Core Inhibitor for the Treatment of Hepatitis B Virus",2019-07-08 07:32:00-04:00,ENTA,negative
425806.0,"Enanta Pharmaceuticals Q2 EPS $0.2 Beats $(0.06) Estimate, Sales $39.631M Miss $40.88M Estimate",2019-05-07 16:01:00-04:00,ENTA,negative
425807.0,"Enanta Pharma To Present Preclinical Data From Hep B, NASH Programs At Int'l. Liver Congress",2019-04-11 10:13:00-04:00,ENTA,neutral
425808.0,Enanta Pharma shares are trading lower after the company announced a 1.6M share common stock offering at $97 per share.,2019-03-20 08:38:00-04:00,ENTA,positive
425809.0,Enanta Pharmaceuticals Completes Enrollment In Two Ongoing Phase 2 Studies,2019-03-18 07:32:00-04:00,ENTA,neutral
425810.0,"Enanta Pharmaceuticals Q1 EPS $1.25 Misses $1.47 Estimate, Sales $69.886M Miss $73.02M Estimate",2019-02-06 16:13:00-05:00,ENTA,negative
425811.0,"Enanta Pharma Will Offer Updates On R&D Programs, Business Outlook At JP Morgan Healthcare Conf. On Jan. 7",2019-01-03 08:12:00-05:00,ENTA,positive
425812.0,"Berenberg Initiates Coverage On Enanta Pharmaceuticals with Buy Rating, Announces $80 Price Target",2018-12-13 09:44:00-05:00,ENTA,neutral
425813.0,"Enanta Pharma Q4 EPS $1.30 Beats $1.19 Estimate, Sales $67.205M Miss $68.52M Estimate",2018-11-26 16:13:00-05:00,ENTA,negative
425814.0,"Enanta Pharma Reports Phase 1 Results, Initiation Of Phase 2a Study Of EDP-938 For Respiratory Syncytial Virus",2018-10-23 07:34:00-04:00,ENTA,neutral
425815.0,Oppenheimer Downgrades Enanta Pharmaceuticals to Perform,2018-08-08 08:15:00-04:00,ENTA,neutral
425816.0,"Enanta Pharmaceuticals Q3 EPS $0.97 Misses $0.98 Estimate, Sales $57.3M Beat $56.93M Estimate",2018-08-07 16:10:00-04:00,ENTA,negative
425817.0,"Roth Capital Initiates Coverage On Enanta Pharmaceuticals with Buy Rating, Announces $133 Price Target",2018-06-06 08:20:00-04:00,ENTA,neutral
425818.0,"Oppenheimer Initiates Coverage On Enanta Pharmaceuticals with Outperform Rating, Announces $135 Price Target",2018-05-24 16:12:00-04:00,ENTA,neutral
425819.0,"RBC Capital Global Healthcare Conference Begins Today, Presenters Include: Chemed, Revance, Eagle Pharma, Enanta, Gilead, TransEnterix, Immunogen, and Incyte",2018-02-21 07:14:00-05:00,ENTA,neutral
425820.0,"Leerink Partners Global Healthcare Conference Begins Today, Presenters Include: Dova Pharma, Heron Therapeutics, Sage Therapeutics, Enanta, The Medicines Company, Puma Biotech, Dicerna Pharma, Biogen, bluebird bio, and Alexion Pharma",2018-02-14 07:06:00-05:00,ENTA,neutral
425821.0,JP Morgan Downgrades Enanta Pharmaceuticals to Neutral,2018-02-08 09:07:00-05:00,ENTA,positive
425822.0,"Enanta Pharma Reports Q1 EPS $0.59 vs $(0.26) In Same Qtr. Last Year, Sales $38.1M vs $31M Est.",2018-02-07 16:14:00-05:00,ENTA,neutral
425823.0,Enanta Pharma Offers Update On R&D Programs,2018-01-05 07:34:00-05:00,ENTA,neutral
425824.0,RBC Capital Downgrades Enanta Pharmaceuticals to Sector Perform,2018-01-02 06:27:00-05:00,ENTA,neutral
425825.0,Enanta Says AbbVie's MAVIRET Is Now Available In Japan For Treatment Of GT1-6,2017-11-30 07:30:00-05:00,ENTA,neutral
425826.0,"Enanta Pharmaceuticals Reports Q4 EPS $1.86 vs $2.13 Est., Sales $75.9M vs $73.12M Est.",2017-11-20 16:03:00-05:00,ENTA,neutral
425827.0,"Enanta Pharmaceuticals Announces 'Positive' Phase 1 a/b Clinical Results for its Lead FXR Agonist, EDP-305",2017-10-23 07:33:00-04:00,ENTA,neutral
425828.0,Enanta Pharma Says AbbVie's MAVIRET Received Approval in Japan for Treatment of Chronic Hepatitis C,2017-09-27 06:30:00-04:00,ENTA,positive
425829.0,"Cantor Fitzgerald Global Healthcare Conference Begins Today, Presenters Include: Verastem, Advaxis, Exelixis, Heron Therapeutics, and Enanta Pharma",2017-09-25 09:30:00-04:00,ENTA,neutral
425830.0,RBC Initiated Coverage On 33 Pharma/Biotech Cos.,2017-09-15 07:38:00-04:00,ENTA,neutral
425831.0,"Baird Global Healthcare Conference Begins Today, Presenters Include: Tenet Healthcare, Mednax, Patterson Companies, Celgene, PerkinElmer, Premier, Acadia Healthcare, Envision Healthcare, and Enanta Pharmaceuticals",2017-09-06 09:11:00-04:00,ENTA,neutral
425832.0,"Enanta Pharmaceuticals Q3 EPS $(0.44) vs $(0.48) Est., Sales $7.5M vs $8.14M Est.",2017-08-07 16:17:00-04:00,ENTA,neutral
425833.0,"Adam Feuerstein Tweets: $GILD competition. 

And $ENTA gets a piece of Mavyret.",2017-08-03 15:10:00-04:00,ENTA,neutral
425834.0,Enanta To Receive $25M Milestone Payment From AbbVie Following EU Marketing Authorization For MAVIRET,2017-07-28 11:07:00-04:00,ENTA,neutral
425835.0,JMP Securities Upgrades Enanta Pharmaceuticals to Market Outperform,2017-07-11 06:08:00-04:00,ENTA,positive
425836.0,Enanta Gives Update on EDP-938,2017-06-26 07:32:00-04:00,ENTA,neutral
425837.0,"Enanta Pharma Reports Q2 EPS $(0.28) vs $(0.38) Est., Sales $9M vs $9.19M Est.",2017-05-08 16:42:00-04:00,ENTA,neutral
425838.0,Enanta Pharma Reports 8 Weeks of AbbVie's G/P Achieved High SVR Rates in Challenging-to-Treat Genotype 3 Chronic HCV Patients,2017-04-21 06:20:00-04:00,ENTA,neutral
425839.0,"AbbVie Says 'new data demonstrated high SVR(12) rates across compensated cirrhotic patients with genotype 1, 2, 4, 5 or 6 chronic HCV infection with 12 weeks of treatment'",2017-04-20 07:35:00-04:00,ENTA,neutral
425840.0,"H.C. Wainwright Holding NASH Investor Conference Today; Attendees Include Allergan, Enanta Pharma, Madrigal Pharma, Vascular Biogenics, Albireo Pharma, CymaBay, Gemphire Therapeutics, And Galectin Therapeutics",2017-04-03 08:28:00-04:00,ENTA,neutral
425841.0,Enanta Announces Positive Opinion for AbbVie's VIEKIRAX,2017-02-27 06:02:00-05:00,ENTA,positive
425842.0,"Enanta Pharmaceuticals Reports Q1 EPS $(0.26) vs $(0.18) Est, Revenue $10.4M vs $11.94M Est",2017-02-08 16:02:00-05:00,ENTA,neutral
425843.0,"JP Morgan Healtchare Conf. Continues Today; Presenters Include Novocure, Zoetis, Oxford Immunotec, Enanta, Irhythm Tech, Walgreen's, & Mylan",2017-01-11 08:34:00-05:00,ENTA,positive
425844.0,FDA Grants Fast Track Designation to Enanta's FXR Agonist Candidate EDP-305 For NASH,2017-01-04 07:32:00-05:00,ENTA,positive
425845.0,JMP Securities Downgrades Enanta Pharmaceuticals to Market Perform,2016-04-28 13:42:00-04:00,ENTA,positive
425846.0,Enanta Announces New Data on VIEKIRA PAK in Patients with Chronic Hepatitis C Virus Infection With or Without Compensated Cirrhosis,2015-11-15 10:00:00-05:00,ENTA,neutral
425847.0,"Barclays Downgrades Enanta Pharmaceuticals to Underweight, Lowers PT to $16.00",2015-10-23 05:03:00-04:00,ENTA,negative
425848.0,AbbVie's VIEKIRAX Approved in Japan for the Treatment of Genotype 1 Chronic Hepatitis C,2015-09-28 04:04:00-04:00,ENTA,positive
425849.0,"AbbVie Announces Primary, Secondary Endpoints Met for Investigational Hep C Treatment in Japanese Patients Without Cirrhosis",2015-05-26 20:02:00-04:00,ENTA,neutral
425850.0,"Enanta Announces  95% SVR12 Results from AbbVie GIFT-1 Study in Non-cirrhotic, Japanese Patients with Genotype 1b Hep C Virus1",2015-05-26 20:01:00-04:00,ENTA,neutral
425851.0,AbbVie Presents Preliminary Phase 3b Data with VIEKIRAX + EXVIERA in Chronic Hep C Patients with Renal Impairment at ILC 2015,2015-04-25 11:55:00-04:00,ENTA,neutral
425852.0,"FDA Accepts NDA, Grants Priority Review to AbbVie for OBV/PTV/r With RBV",2015-04-24 04:28:00-04:00,ENTA,positive
425853.0,Enanta Pharmaceuticals Announces AbbVie's Investigational Treatment Regimen for Genotype 1 Chronic Hepatitis C Granted Priority Review in Japan,2015-04-15 21:27:00-04:00,ENTA,positive
425854.0,"Deutsche Bank Initiates Coverage on Enanta Pharmaceuticals at Buy, Announces $42.00 PT",2015-04-06 07:10:00-04:00,ENTA,neutral
425855.0,"Barclays Initiates Coverage on Enanta Pharmaceuticals at Equal-weight, Announces $35.00 PT",2015-03-04 06:44:00-05:00,ENTA,neutral
425856.0,"AbbVie Submits NDA in Japan for its Investigational, All-Oral, Treatment for Chronic Hepatitis C",2015-02-12 05:47:00-05:00,ENTA,neutral
425857.0,EC Grants Marketing Authorizations for AbbVie's VIEKIRAX + EXVIERA for Treatment of Chronic Hepatitis C,2015-01-16 04:39:00-05:00,ENTA,positive
425858.0,Enanta Announces  FDA Approval for AbbVie's VIEKIRA PAK,2014-12-22 05:10:00-05:00,ENTA,positive
425859.0,Enanta Pharma Reports Q3 EPS of $(0.27) vs $(0.33) Est; Revenue of $2.60M vs $3.81M Est,2014-11-24 07:31:00-05:00,ENTA,neutral
425860.0,"FBR Capital Maintains Outperform on Enanta Pharma, Lowers PT to $50.00",2014-10-21 09:16:00-04:00,ENTA,negative
425861.0,Enanta Pharma Reports Q3 EPS of $2.61 vs $1.67 Est; Revenue of $42.10M vs $40.83M Est,2014-08-11 07:34:00-04:00,ENTA,neutral
425862.0,Enanta Pharmaceuticals Announces Novartis Advanced EDP-239 into Combination Studies with Alisporivir ,2014-08-07 08:35:00-04:00,ENTA,positive
425863.0,"JMP Securities Downgrades Enanta Pharma to Market Perform, Removes $50.00 PT",2014-07-07 06:32:00-04:00,ENTA,positive
425864.0,"Baird Downgrades Enanta Pharma to Neutral, Maintains $41.00 PT",2014-06-24 06:52:00-04:00,ENTA,neutral
425865.0,"Macquarie Initiates Coverage on Enanta Pharma at Outperform, Announces $18.00 PT",2014-06-17 06:39:00-04:00,ENTA,neutral
425866.0,AbbVie to Present Detailed Phase III Results from SAPPHIRE-I and SAPPHIRE-II Studies in Chronic Hepatitis C Patients at ILC 2014,2014-04-11 05:35:00-04:00,ENTA,neutral
425867.0,AbbVie to Present Detailed Results from Phase III Studies in Patients with Chronic Hepatitis C at ILC,2014-03-24 05:36:00-04:00,ENTA,neutral
425868.0,Enanta Pharmaceuticals Announces Eight Studies Have Been Accepted for Presentation at ILC,2014-03-24 05:35:00-04:00,ENTA,positive
425869.0,Enanta Pharma Reports Q1 EPS of $(0.30) vs $(0.15) Est; Revenue of $893.0K vs $1.41M Est,2014-02-13 07:36:00-05:00,ENTA,neutral
425870.0,Enanta Pharmaceuticals Announces Additional Data from AbbVie's M13-393 Study to be Presented at Liver Meeting,2013-11-03 10:10:00-05:00,ENTA,neutral
425871.0,Enanta Pharma Reports Q3 EPS of $(0.23) vs $(0.34) Est,2013-08-12 07:31:00-04:00,ENTA,neutral
425872.0,Enanta Pharma Reports Q2 EPS of $(2.28) Which May Not Compare $(0.34) Est,2013-05-08 08:26:00-04:00,ENTA,neutral
425873.0,Enanta Announces Data from Phase 2b Study for ABT-450 for Hepatitis C ,2013-04-23 06:57:00-04:00,ENTA,neutral
425874.0,"Credit Suisse Initiates Coverage on Enanta Pharma at Outperform, Announces $29.00 PT",2013-04-15 09:40:00-04:00,ENTA,positive
425875.0,Leerink Swann Initiates Coverage on Enanta Pharma at Outperform,2013-04-15 09:08:00-04:00,ENTA,neutral
425876.0,"JMP Securities Initiates Coverage on Enanta Pharma at Market Outperform, Announces $25.00 PT",2013-04-15 09:08:00-04:00,ENTA,positive
425877.0,"JP Morgan Initiates Coverage on Enanta Pharma at Overweight, Announces $25.00 PT",2013-04-15 06:19:00-04:00,ENTA,neutral
425878.0,"Enanta Pharma Files $69M IPO, Will Trade on NASDAQ",2012-11-06 16:10:00-05:00,ENTA,neutral
